<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although the blast percentage in the bone marrow (BM) is a key parameter for the classification of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), the current blast percentages used to define <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> subtypes have not been shown to have strong biological relevance </plain></SENT>
<SENT sid="1" pm="."><plain>We determined the blast phenotypes and examined their relationship with the BM blast percentage in 90 MDS cases </plain></SENT>
<SENT sid="2" pm="."><plain>When the BM blast percentage increased, cases whose blasts expressed CD7, CD56 and CD117 increased whereas cases whose blasts expressed CD10, CD11b and CD15 decreased </plain></SENT>
<SENT sid="3" pm="."><plain>The BM blast percentages where the blast immunophenotype changed were 5, 10, 20 and 25% </plain></SENT>
<SENT sid="4" pm="."><plain>Blast immunophenotypes have the potential to provide a biological basis for and refine the present <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> classifications </plain></SENT>
</text></document>